LY2886721 – 25 mg

Brand:
Cayman
CAS:
1262036-50-9
Storage:
-20
UN-No:
De Minimis - 3077 / 9

LY2886721 selectively inhibits the β-site amyloid protein cleaving enzyme (BACE) (IC50 = 20 nM for recombinant hBACE1).{33660} BACE performs the first cleavage step in the Aβ cascade; thus, its inhibition by LY2886721 decreases production of all forms of the Aβ peptide.{33661} A Phase II clinical study for the use of LY2886721 in the treatment of Alzheimer’s disease was terminated early due to abnormal liver biochemistry values in several patients. The toxic effects did not appear to be due to BACE inhibition.  

 

Out of stock

SKU: 21599 - Category:

Description

Selective inhibitor of BACE (IC50 = 20 nM for recombinant hBACE1)


Formal name: N-[3-[(4aS,7aS)-2-amino-4a,5-dihydro-4H-furo[3,4-d][1,3]thiazin-7a(7H)-yl]-4-fluorophenyl]-5-fluoro-2-pyridinecarboxamide

Synonyms:  β-Secretase

Molecular weight: 390.4

CAS: 1262036-50-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Neuroscience|Neurodegenerative Disorders|Alzheimer’s Disease